<DOC>
	<DOCNO>NCT01479595</DOCNO>
	<brief_summary>This study design investigate efficacy safety QBX258 subject moderate severe asthma .</brief_summary>
	<brief_title>A Study Establish Efficacy QBX258 Patients With Moderate Severe Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Patients atopic asthma &gt; 1 year duration diagnose accord GINA guideline . Subjects must weigh least 50 kg participate study , must body mass index ( BMI ) within range 18 39 kg/m2 . Asthma adequately control current treatment , demonstrate Asthma Control Questionnaire ( ACQ ) score &gt; 1.5 . FEV1 40 90 % predict . Diagnosed COPD define GOLD guideline Subjects respiratory tract infection within 4 week prior screen . Women childbearing potential must use highly effective method contraception dose least 18 week last study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Interleukin</keyword>
	<keyword>QBX258</keyword>
	<keyword>QAX576</keyword>
	<keyword>VAK694</keyword>
</DOC>